4 results on '"ZHU Jiye"'
Search Results
2. Lysyl Oxidase Is Predictive of Unfavorable Outcomes and Essential for Regulation of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma.
- Author
-
Zhu, Jiye, Huang, Shan, Wu, Guobin, Huang, Chaoyuan, Li, Xianjian, Chen, Zhigang, Zhao, Lei, and Zhao, Yinnong
- Subjects
- *
LYSYL oxidase , *VASCULAR endothelial growth factors , *LIVER cancer , *METASTASIS , *STATISTICAL correlation , *CANCER invasiveness , *IMMUNOHISTOCHEMISTRY , *REVERSE transcriptase polymerase chain reaction , *BIOCHEMISTRY , *CELL physiology , *CELLULAR signal transduction , *GENES , *HEPATOCELLULAR carcinoma , *LIVER tumors , *PHENOMENOLOGY , *MULTIVARIATE analysis , *NEEDLE biopsy , *NONPARAMETRIC statistics , *OXIDOREDUCTASES , *PROGNOSIS , *STATISTICAL sampling , *SURVIVAL analysis (Biometry) , *WESTERN immunoblotting , *PREDICTIVE tests , *PROPORTIONAL hazards models , *KAPLAN-Meier estimator , *CANCER cell culture - Abstract
Background: Lysyl oxidase (LOX) is frequently overexpressed in a variety of malignancies and involved in tumor invasion and metastasis. Furthermore, it has been shown that LOX is closely related to vascular endothelial growth factor (VEGF).Aims: In this study, we aimed to investigate the exact role of LOX and the correlation between LOX and VEGF in hepatocellular carcinoma (HCC).Methods: The expression levels of LOX in HCC tissue and adjacent noncancerous tissue were evaluated by quantitative reverse transcription polymerase chain reaction and immunohistochemical analysis. The effect of LOX knockdown on cell proliferation, migration, and invasion was investigated in vitro. The role of LOX in the regulation of VEGF was further characterized in HCC cells that had been treated with transforming growth factor beta (TGF-β).Results: Our study showed that LOX was up-regulated in HCC cell lines and tissue. HCC patients with elevated expression of LOX had relatively shorter disease-free survival and overall survival. Knockdown of LOX reduced the proliferation, migration, and invasion of HCC cells. Additionally, the expression level of LOX positively correlated with that of VEGF. After treatment with TGF-β, the levels of LOX and VEGF were both up-regulated in a dose-dependent manner. In the cells treated with siRNA of LOX, levels of VEGF and phosphorylated p38 were significantly decreased and could not be up-regulated by TGF-β. Inhibition of p38 MAPK signaling abrogated TGF-β-mediated up-regulation of VGEF but did not affect LOX expression.Conclusions: LOX appears to be a predictor of less favorable outcomes and may regulate the expression of VEGF via p38 MAPK signaling. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
3. Plasmacytoid dendritic cells recruited by HIF-1α/eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma.
- Author
-
Pang, Li, Ng, Kevin Tak-Pan, Liu, Jiang, Yeung, Wai-Ho Oscar, Zhu, Jiye, Chiu, Tsz-Ling Shirley, Liu, Hui, Chen, Zhiwei, Lo, Chung-Mau, Man, Kwan, Ng, Kevin T P, Yeung, Oscar W H, and Chiu, T L Shirley
- Subjects
- *
REGULATORY T cells , *DENDRITIC cells , *HEPATOCELLULAR carcinoma , *ASCITIC fluids , *LABORATORY mice , *PROGNOSIS , *IMMUNOSUPPRESSION , *TUMOR microenvironment , *ADENOSINES - Abstract
Plasmacytoid dendritic cells (pDCs) play immunosuppressive roles in the tumor microenvironment (TME). However, the molecular mechanisms underlying the recruitment and dysfunction of pDCs in the TME remain largely elusive, especially in hepatocellular carcinoma (HCC). In this study, we observed the accumulation of pDCs in the blood, tumor tissue, and ascitic fluid of HCC patients. A high density of tumor-infiltrating pDCs was correlated with poor prognosis in patients with HCC. Hypoxia-induced extracellular adenosine (eADO) significantly enhanced pDC recruitment into tumors via the adenosine A1 receptor (ADORA1). Mechanistically, hypoxia-inducible factor 1-alpha (HIF-1α) transcriptionally upregulated the expression of the ectonucleotidases CD39 and CD73 in HCC cells, both of which are essential for the generation of eADO. Moreover, eADO-stimulated pDCs promoted the induction of regulatory T cells and suppressed proliferation and cytotoxicity of CD8+ T cells. Depletion of pDCs using a monoclonal antibody or an ADORA1 antagonist significantly improved antitumor immunity and suppressed HCC growth in the immunocompetent HCC mouse model. Thus, targeting pDC recruitment may serve as a potential adjuvant strategy for immunotherapies in HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Postoperative Complications and Survival Analysis of Surgical Resection for Hilar Cholangiocarcinoma: A Retrospective Study of Fifty-Nine Consecutive Patients.
- Author
-
Zhu, Weihua, Xie, Wenyong, Zhang, Zhedong, Li, Shu, Zhang, Dafang, Liu, Yijun, Zhu, Jiye, and Leng, Xisheng
- Subjects
- *
SURGICAL excision , *SURGICAL complications , *SURVIVAL analysis (Biometry) , *CHOLANGIOCARCINOMA , *REGRESSION analysis , *CHOLANGITIS - Abstract
Hilar cholangiocarcinoma (HC) is invariably fatal without surgical resection. The primary aim of the current study was to determine the safety of variable surgical resections for patient with HC and their survival after surgical resection. In addition, prognostic factor for the overall survival was also evaluated. The study included 59 consecutive patients who were newly diagnosed with HC and underwent surgical resections with curative intend between February 2009 and February 2017. Patients were followed up at 3-6 months intervals after hospital discharge. Postoperative complications and overall survival were determined. Associations of clinicopathologic and surgeon-related factors with overall survival were evaluated through univariate analysis and Cox regression analysis. Of patients with Bismuth and Corlette (B & C) type III (n = 19) and IV (n = 25) HC lesions, 33 (55.9%) were treated with hilar resection combined with major liver resection (MLR), while the other 11 patients with type III and IV, and those with type I (n = 8) and II (n = 7) HC lesions were treated with hilar resection. The overall surgical mortality was 5.1% and surgical morbidity was 35.6%. There was no statistical difference in the mortality between MLR group and hilar resection group (6.1% vs. 3.8%; X 2 = 0.703, P = 0.145). The median follow-up period was 18 months (range, 1-94 months). The 1-, 3-, 5-year survival rate was 59.3%, 36.5%, and 17.7%, respectively. The overall survival after resections was 18 months. In HC patients with B & C type III and IV lesions, the median survival was 23 months for hilar resection with MLR and 8 months for hilar resection alone; the 1-, 3-, 5-year cumulative survival rate was 63.9%, 23.3%, and 15.5%, respectively for hilar resection with MLR, and 11.1%, 0, and 0, respectively for hilar resection alone, with significant differene observed (HR, 9.902; 95% CI, 2.636-19.571, P = 0.001). Four factors were independently associated with overall survival: preoperative serum Ca19-9 (HR, 7.039; 95% CI, 2.803-17.678, P <0.001), histopathologic grade (HR, 4.964; 95% CI, 1.046-23.552, P = 0.044), surgical margins (P = 0.031), and AJCC staging (P = 0.015). R0 resection is efficacious in surgical treatment of HC. MLR in combination with caudate lobe resection may increase the chance of R0 resection and improve survival of HC patients with B & C type III and IV lesions. Preoperatively prepared for biliary drainage may ensure the safety of MLR in most HC patients. Novel adjuvant therapies are needed to improve the survival of HC patients with poor prognostic factors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.